Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Leukemia

Welcome to the Leukemia Channel

VJHemOnc brings you the latest updates in leukemia directly from the experts. Alongside our world-leading Editorial Board, The Leukemia Channel covers all of the latest updates in leukemia presented at international congresses – including video interviews, podcasts, roundtable discussions and more.

Jump into The Leukemia Channel to learn more about the latest advances in therapy, including CAR-T, antibody-based treatments, checkpoint inhibitors and transplantation. As well as updates in treatment, The Leukemia Channel also covers the state-of-the-art in classification, prognostication and diagnosis.

Acute Lymphoblastic Leukemia

View all
New horizons in Ph+ ALL: the evolving role of bispecific antibodies 1:20
New horizons in Ph+ ALL: the evolving role of bispecific antibodies
Josep-Maria Ribera • 14 Sep 2026
NGS-MRD assessment and targeted treatment selection in ALL 1:48
NGS-MRD assessment and targeted treatment selection in ALL
Josep-Maria Ribera • 14 Sep 2026

Acute Myeloid Leukemia

View all
Novel targets, combinations, and treatments in AML: insights from iwAL 2026 19:38
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
Gail Roboz et al. • 7 Oct 2026
SENTI-202: a first-in-class logic-gated off-the-shelf CAR NK-cell therapy for R/R AML 10:42
SENTI-202: a first-in-class logic-gated off-the-shelf CAR NK-cell therapy for R/R AML
Stephen Strickland • 19 Sep 2026

Chronic Lymphocytic Leukemia

View all
Is there a role for CAR T-cell therapy in the treatment pathway for CLL? 1:21
Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
Marco Ruella • 16 Oct 2026
Insights into the current CLL treatment algorithm and emerging research directions 1:51
Insights into the current CLL treatment algorithm and emerging research directions
Matthew Davids • 17 Oct 2026

Chronic Myeloid Leukemia

View all
Beyond the label: optimal dosing strategies for CML in community practice 0:51
Beyond the label: optimal dosing strategies for CML in community practice
Fadi Haddad • 10 Sep 2026
Incorporating patient goals into frontline TKI selection in CML 2:17
Incorporating patient goals into frontline TKI selection in CML
Jorge Cortes • 10 Sep 2026

Acute Promyelocytic Leukemia

View all
Differentiation syndrome in APL: parallels with IDH and menin inhibitors in AML 9:36
Differentiation syndrome in APL: parallels with IDH and menin inhibitors in AML
Stéphane de Botton • 18 Sep 2026
Differentiation syndrome in menin inhibitor-treated patients: recognition, management & next steps 6:18
Differentiation syndrome in menin inhibitor-treated patients: recognition, management & next steps
Eunice Wang et al. • 18 Sep 2026

T-Cell Prolymphocytic Leukemia

View all
Long-term outcomes of alloSCT for T-cell prolymphocytic leukemia 2:07
Long-term outcomes of alloSCT for T-cell prolymphocytic leukemia
Olivier Tournilhac • 8 Dec 2024
The current treatment landscape for patients with T-cell prolymphocytic leukemia 1:23
The current treatment landscape for patients with T-cell prolymphocytic leukemia
Dima El-Sharkawi • 28 Apr 2024

General leukemia

View all
Is there a role for CAR T-cell therapy in the treatment pathway for CLL? 1:21
Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
Marco Ruella • 16 Oct 2026
Insights into the current CLL treatment algorithm and emerging research directions 1:51
Insights into the current CLL treatment algorithm and emerging research directions
Matthew Davids • 17 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals